SRI-81 Shatavari Secures Health Canada NPN for Women's Health Claims

Ottawa, Canada — 10 July 2026

Health Canada has granted a Natural Product Number (NPN) to SRI-81 Shatavari, an extract developed by Ixoreal Biomed. This NPN authorises specific health claims related to the management of menopausal symptoms, support for sexual arousal, and general female well-being. The ingredient is distributed within Canada by CK Nutraceuticals. This regulatory clearance offers a significant opportunity for supplement brands operating in the Canadian market, streamlining the path to product launch with pre-approved health claims.

SRI-81 Shatavari is an extract derived solely from the root of the Asparagus racemosus plant. It is standardised to contain specific levels of Shatavarin IV and total shatavarins, which are key active compounds. Ixoreal Biomed positions this ingredient as a clinically validated option for women seeking natural solutions to menopausal discomfort and enhancements in sexual health. The approval underscores a growing demand for botanical ingredients supported by scientific evidence, particularly in sensitive health areas like women's reproductive health where consumer scrutiny is high.

For manufacturers, the NPN status simplifies the product development cycle by eliminating the need for independent claim substantiation, a process often costly and time-consuming. This ingredient offers a differentiated profile in the crowded women's health category, moving beyond general well-being claims to targeted, symptom-specific benefits sanctioned by a national regulator.

What this means for Canada

Canadian brand owners now possess a de-risked pathway to market for products targeting menopause and sexual health with SRI-81 Shatavari. The NPN allows direct application of approved health claims, reducing compliance expenditure and accelerating time-to-market compared to novel ingredient dossiers. Procurement teams can specify SRI-81 for its standardised active compounds, ensuring product consistency and quality. This regulatory achievement enables brands to directly challenging established market leaders or gain first-mover advantages in specific women's health niches, particularly among consumers seeking natural alternatives to conventional pharmacotherapies. Brands should initiate reformulation strategies now to capitalise on this approved ingredient before competitors flood the market.

The availability of such a specifically approved ingredient also places pressure on other botanical suppliers to provide similar levels of scientific backing and regulatory pre-clearance for their offerings. Brands must consider the competitive implications of not incorporating ingredients with defined NPNs for key market segments.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.